OA12097A - 2,4-Diaminopyrimidine compounds useful as immunosuppressants. - Google Patents
2,4-Diaminopyrimidine compounds useful as immunosuppressants. Download PDFInfo
- Publication number
- OA12097A OA12097A OA1200200156A OA1200200156A OA12097A OA 12097 A OA12097 A OA 12097A OA 1200200156 A OA1200200156 A OA 1200200156A OA 1200200156 A OA1200200156 A OA 1200200156A OA 12097 A OA12097 A OA 12097A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- dihydro
- aryl
- heteroaryl
- composition according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (16)
12097 Λ -55- 7,8-Dihydro-6H-pynmido[5,4-b}[1,4]thiazine; 3,4-Dihydro-2H-1-thia-4,5,8-tnaza-naphthaiene;6,7-Dihydro-5H-8-thia-1,2,4,5-tetraaza-naohthaiene; 7,8-Dihydro-6H-5-thia-1.2,4,8-tetraaza-naphthalene; 7,8-Dihydro-5H-5-thia-1,2,3,8-tetraaza-naphthaiene; 6,7-Dihydfo-5H-8-thia- 1,2,3,5-tetraaza-naphthaiene; 5,6,7,8-Tetra'nydro-pyrido[3,2-d]pyrimidine; 1,2,3,4-Tetrahydro-pyndo[2,3~d]pyridazine, 5,6,7,8-Tetrahydro-pyrido[2,3-bjpyrazine; 5,6,7,8-Tetrahydro-pyrido[3,2-e][1,2,4]triazine, 5,6,7,8-Tetrahydro-pyrido{2,3-eJ[1,2,4]triazine; 5,6,7,8-Tsirahydro-pyrido[3,2-d][1,2,3]triazine; and 5,6,7,8-Tetrahydro-pyrido[2,3-d][1,2,3}triazine.
15. A pharmaceutical composition comprising an effective amount of acompouna according to ciaim 1, and a pharmaceutical carrier. 16 A pharmaceutical composition according to ciaim 15, for treatment orprévention of a condition in a mammai wherein therapeutic benefit is achieved by modulationof a T-cel! mediated ceiiuiar process. 17 A pharmaceutical composition according to ciaim 15, for treatment orprévention of transpiant rejection in a mammai
18. A pnarmaceutica! composition according to ciaim 15, for treatment orprévention of autoimmune disease in a mammai.
19. A pharmaceutical composition according to ciaim 15, for treatment orprévention of infiammatory disease in a mammai.
20. A pharmaceutical composition according to ciaim 15, for treatment orprévention of aiiergy in a mammai
21. A pharmaceutica! composition according to ciaim 15, for treating 7-ceüieukemia or T-ceil iymphoma in a mammai. 22 A pharmaceutical composition according fc ciaim 15, for the treatment of adisease in a mammai wherein treatment can be effected by inhibiting activation of T-ceils, orthe results of said activation.
23. A pharmaceutical composition according to ciaim 15, further comprising anadditions! agent which modulâtes the mammaiian immune System or wnich is an arsti-inflammatory agent.
24. A pharmaceutical composition according to ciaim 15, usefui in the treatmentof a disorder or condition in a mammai seiected from the aroup consistina of ssthma, haylever, hives, infantile eczema, atopie dermatitis, and other allergie diseases invoivingantibody-mediated (intermediate-type) hvpersensitivity réactions, transpiant rejection,psoriasis, uteerative coiitis, Crohn's disease, iupus, multiple scierosis, rheurnatoid arthritis,type I diabètes, autoimmune thyroid disorders, T-cel! maiignancies mciuding T-ce!1 ieukemiaand T-cel! iymphoma, and Aizhetmer’s disease
25. A pharmaceutical composition according to ciaim 15, usefui to inhibiî tyrosinekinase Lck in a mammai. -56- 1 2097 26 A pharmaceutical composition according to ciasm 16, whersîn said ccmpcunclis proviasd as a pharmacsutically acceptable sait, solvaie or hycrate thereci.
27. Use of a composition of claim 15 in the manufacture of a substance foruse in a method of inhibiting protein tyrosine kinase Lck in a mammal.
28. The use of claim 27 wherein one or more additional agents thatmodulate a mammalian immune response or which are anti-inflammatory agents areused separately or in combination with said composition.
29. Use of a composition according to claim 15 effective in treating orpreventing a disorder or condition selected from asthma, hay fever, hives, infantileeczema, atopie dermatitis, and other allergie diseases involving antibody-mediated(intermediate-type) hypersensitivity reactions, transplant rejection, psoriasis,ulcerative colitis, Crohn’s disease, lupus, multiple sclerosis, rheumatoid arthritis, type1 diabètes, autoimmune thyroid disorders, T-cell malignancies including T-cellleukemia and T-cell lymphoma, and Alzheimer’s disease in the manufacture of amédicament for use in a said method.
30. Use of a pharmaceutical composition according to claim 15, in themanufacture of a médicament for use in a method for treating or preventing transplantrejection in a mammal.
31. Use of a pharmaceutical composition according to claim 15, in themanufacture of a médicament for use in a method for treating or preventingautoimmune disease in a mammal.
32. Use of a pharmaceutical composition according to claim 15, in themanufacture of a médicament for use in a method for treating or preventinginflammatory disease in a mammal.
33. Use of a pharmaceutical composition according to claim 15, in themanufacture of a médicament for use in a method for treating or preventing allergiedisease in a mammal.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16822499P | 1999-11-30 | 1999-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA12097A true OA12097A (en) | 2006-05-04 |
Family
ID=22610621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200200156A OA12097A (en) | 1999-11-30 | 2000-11-09 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants. |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1242403B1 (fr) |
JP (1) | JP3955468B2 (fr) |
KR (1) | KR20020059826A (fr) |
CN (1) | CN1402720A (fr) |
AP (1) | AP2002002530A0 (fr) |
AT (1) | ATE315036T1 (fr) |
AU (1) | AU1047601A (fr) |
BG (1) | BG106695A (fr) |
BR (1) | BR0015995A (fr) |
CA (1) | CA2392971C (fr) |
CO (1) | CO5261519A1 (fr) |
CZ (1) | CZ20021703A3 (fr) |
DE (1) | DE60025385T2 (fr) |
EA (1) | EA200200411A1 (fr) |
EE (1) | EE200200275A (fr) |
ES (1) | ES2253266T3 (fr) |
GT (1) | GT200000200A (fr) |
HN (1) | HN2000000264A (fr) |
HU (1) | HUP0203300A3 (fr) |
IL (1) | IL149103A0 (fr) |
IS (1) | IS6339A (fr) |
MA (1) | MA26846A1 (fr) |
MX (1) | MXPA02005350A (fr) |
NO (1) | NO20022557L (fr) |
OA (1) | OA12097A (fr) |
PA (1) | PA8506801A1 (fr) |
PE (1) | PE20010900A1 (fr) |
PL (1) | PL355946A1 (fr) |
SV (1) | SV2002000231A (fr) |
TN (1) | TNSN00232A1 (fr) |
TR (1) | TR200201431T2 (fr) |
UY (1) | UY26455A1 (fr) |
WO (1) | WO2001040215A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02007957A (es) * | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
IL154016A0 (en) * | 2000-08-31 | 2003-07-31 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
ATE326458T1 (de) | 2000-09-15 | 2006-06-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
DK1353916T3 (da) | 2000-12-21 | 2007-01-29 | Vertex Pharma | Pyrazolforbindelser der er egnede som proteinkinaseinhibitorer |
WO2003030909A1 (fr) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- et 4-aminopyrimidines n-substituees par un noyau bicyclique utilisees comme inhibiteurs de kinases dans le traitement du cancer |
CN101037438A (zh) | 2002-08-02 | 2007-09-19 | 沃泰克斯药物股份有限公司 | 用作gsk-3的抑制剂的吡唑组合物 |
US20040204458A1 (en) | 2002-08-16 | 2004-10-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of Lck inhibitors for treatment of immunologic diseases |
DE10237423A1 (de) * | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
CN1910159A (zh) * | 2004-01-16 | 2007-02-07 | 诺瓦提斯公司 | 2,4-二氨基嘧啶和它们用于诱导心肌发生的用途 |
WO2006044405A1 (fr) * | 2004-10-12 | 2006-04-27 | Decode Genetics, Inc. | Composés bicycliques de type arylsulfonamide péri-substitués pour le traitement de l’artériopathie oblitérante |
US20060161001A1 (en) * | 2004-12-20 | 2006-07-20 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
NZ570530A (en) | 2006-02-14 | 2011-09-30 | Vertex Pharma | Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives |
MX2008011661A (es) * | 2006-03-16 | 2008-09-22 | Novartis Ag | Compuestos organicos heterociclicos para el tratamiento de melanoma en particular. |
CA2685860A1 (fr) | 2007-05-10 | 2008-11-20 | Amr Technology, Inc. | Tetrahydrobenzo-l,4-diazepines substituees par un aryle ou un heteroaryle et utilisation desdites dans le blocage de la reassimilation de la norepinephrine, de la dopamine et de la serotonine |
KR101536021B1 (ko) * | 2007-10-16 | 2015-07-10 | 다이이찌 산쿄 가부시키가이샤 | 피리미딜 인돌린 화합물 |
EP2480553A2 (fr) | 2009-09-25 | 2012-08-01 | Vertex Pharmaceuticals Incorporated | Procédé pour préparer des dérivés de pyrimidine utilisés en tant qu'inhibiteurs de protéines kinases |
JP2013505927A (ja) | 2009-09-25 | 2013-02-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピリミジン誘導体の調製方法 |
TWI513694B (zh) * | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
KR101708761B1 (ko) * | 2012-04-13 | 2017-02-21 | 주식회사 머쉬메드 | 퓨린 유도체 또는 그의 염을 포함하는 아토피성 피부염의 예방 또는 치료용 조성물 |
EP3055301B1 (fr) * | 2013-10-07 | 2019-11-20 | Kadmon Corporation, LLC | Dérivés de (2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amine en tant qu'inhibiteurs de kinase rho pour le traitement de maladies auto-immunes |
WO2019001572A1 (fr) * | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Inhibiteur de protéine kinase associée à rho, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation |
KR102563325B1 (ko) * | 2017-06-30 | 2023-08-03 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Rho-관련 단백질 키나아제 억제제, Rho-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도 |
US10323023B2 (en) | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
EP0837063A1 (fr) * | 1996-10-17 | 1998-04-22 | Pfizer Inc. | Dérivés de 4-aminoquinazoline |
GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
-
2000
- 2000-11-09 CA CA002392971A patent/CA2392971C/fr not_active Expired - Fee Related
- 2000-11-09 ES ES00971650T patent/ES2253266T3/es not_active Expired - Lifetime
- 2000-11-09 IL IL14910300A patent/IL149103A0/xx unknown
- 2000-11-09 AU AU10476/01A patent/AU1047601A/en not_active Abandoned
- 2000-11-09 EE EEP200200275A patent/EE200200275A/xx unknown
- 2000-11-09 EA EA200200411A patent/EA200200411A1/ru unknown
- 2000-11-09 EP EP00971650A patent/EP1242403B1/fr not_active Expired - Lifetime
- 2000-11-09 AP APAP/P/2002/002530A patent/AP2002002530A0/en unknown
- 2000-11-09 JP JP2001541899A patent/JP3955468B2/ja not_active Expired - Fee Related
- 2000-11-09 OA OA1200200156A patent/OA12097A/en unknown
- 2000-11-09 TR TR2002/01431T patent/TR200201431T2/xx unknown
- 2000-11-09 CZ CZ20021703A patent/CZ20021703A3/cs unknown
- 2000-11-09 DE DE60025385T patent/DE60025385T2/de not_active Expired - Lifetime
- 2000-11-09 KR KR1020027006941A patent/KR20020059826A/ko not_active Application Discontinuation
- 2000-11-09 CN CN00816506A patent/CN1402720A/zh active Pending
- 2000-11-09 HU HU0203300A patent/HUP0203300A3/hu unknown
- 2000-11-09 PL PL00355946A patent/PL355946A1/xx not_active Application Discontinuation
- 2000-11-09 WO PCT/IB2000/001628 patent/WO2001040215A1/fr active IP Right Grant
- 2000-11-09 AT AT00971650T patent/ATE315036T1/de not_active IP Right Cessation
- 2000-11-09 BR BR0015995-6A patent/BR0015995A/pt not_active Application Discontinuation
- 2000-11-09 MX MXPA02005350A patent/MXPA02005350A/es active IP Right Grant
- 2000-11-22 PA PA20008506801A patent/PA8506801A1/es unknown
- 2000-11-23 HN HN2000000264A patent/HN2000000264A/es unknown
- 2000-11-28 PE PE2000001268A patent/PE20010900A1/es not_active Application Discontinuation
- 2000-11-28 UY UY26455A patent/UY26455A1/es not_active Application Discontinuation
- 2000-11-29 SV SV2000000231A patent/SV2002000231A/es unknown
- 2000-11-29 TN TNTNSN00232A patent/TNSN00232A1/fr unknown
- 2000-11-29 GT GT200000200A patent/GT200000200A/es unknown
- 2000-11-30 CO CO00091745A patent/CO5261519A1/es unknown
-
2002
- 2002-04-12 IS IS6339A patent/IS6339A/is unknown
- 2002-05-13 BG BG106695A patent/BG106695A/bg unknown
- 2002-05-28 MA MA26655A patent/MA26846A1/fr unknown
- 2002-05-29 NO NO20022557A patent/NO20022557L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7101869B2 (en) | 2,4-diaminopyrimidine compounds useful as immunosuppressants | |
CA2392971C (fr) | Composes de 2,4-diaminopyrimidine utilises comme immunodepresseurs | |
TWI699359B (zh) | 4h-吡咯[3,2-c]吡啶-4-酮衍生物 | |
KR102534962B1 (ko) | 8,9-디하이드로이미다졸[1,2-a]피리미도[5,4-e]피리미딘-5(6H)-케톤계 화합물 | |
KR102085121B1 (ko) | 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도 | |
CN103998042B (zh) | Pi3k的活性或功能的抑制剂的应用 | |
JP5487214B2 (ja) | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 | |
TWI534145B (zh) | 四氫吡啶并嘧啶衍生物 | |
AU2019246753A1 (en) | Novel compounds and compositions for inhibition of FASN | |
CA2947002C (fr) | Composes de pyrazole et leur utilisation en tant que bloqueurs des canaux calciques de type t | |
TW200940544A (en) | Inhibitors of PI3 kinase | |
CN106467541A (zh) | 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用 | |
TW201008929A (en) | Organic compounds as Smo inhibitors | |
TW201113267A (en) | Quinazolines as potassium ion channel inhibitors | |
EA017392B1 (ru) | Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ | |
TW202106670A (zh) | 用於治療癌症之醯基磺醯胺 | |
US20200216439A1 (en) | Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones | |
US20230416249A1 (en) | N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer | |
WO2014026467A1 (fr) | Composés de pyrimidine substitués bicycliques |